N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists

Amy Hauck Newman, Jianjing Cao, Christina J. Bennett, Michael J. Robarge, Rebekah A. Freeman, Robert R. Luedtke

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

The dopamine D3 receptor subtype has been targeted as a potential neurochemical modulator of the behavioral actions of psychomotor stimulants, such as cocaine. Previous synthetic studies provided structural requirements for high affinity binding to D3 receptors which included a 2,3-dichloro-phenylpiperazine linked to an arylamido function via a butyl chain. To reduce lipophilicity of these agents and further investigate optimal conformation, a second series of 15 novel ligands was designed that included heteroaromatic substitution and unsaturated alkyl linkers. These compounds were synthesized and evaluated for binding at rat D3 and D2 receptors stably expressed in Sf9 cells. D3 binding affinities ranged from Ki=0.6-1080 nM, with a broad range of D3/D2 selectivities (2-97). The discovery of potent, selective and bioavailable D3 receptor ligands will provide essential molecular probes to elucidate the role D3 receptors play in the psychomotor stimulant and reinforcing effects of cocaine.

Original languageEnglish
Pages (from-to)2179-2183
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume13
Issue number13
DOIs
StatePublished - 7 Jul 2003

Fingerprint Dive into the research topics of 'N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D<sub>3</sub> receptor antagonists'. Together they form a unique fingerprint.

  • Cite this